Skip to main content
2023 IKCS: Europe Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Lisa Pickering, MD, PhD (she/her/hers)

Consultant Medical Oncologist
The Royal Marsden NHS Foundation Trust, United Kingdom

Dr Lisa Pickering
Consultant Medical Oncologist in Renal and Melanoma Cancer,
Royal Marsden, London, UK

Dr Lisa Pickering is a Consultant Medical Oncologist who specialises in the treatment of renal and skin cancers.

Dr Pickering gained an honours degree in Physiological Sciences from the University of Oxford in 1992 and her medical degree in 1995 from the University of London. She trained in Medical Oncology at Guy’s and St Thomas’, St George’s and Royal Marsden Hospitals. She was awarded a PhD from the University of London in 2007.

She was appointed to St George’s and the Royal Marsden in 2008 as a Consultant Medical Oncologist in renal, prostate and penile cancers. At St George’s she was Clinical Lead for Oncology and Palliative Medicine from 2011 and Clinical Chair of the Division of Medicine from 2015 to 2019. During this time she also had an active role in training future medical oncologists as a member of the regional Specialist Training Committee and lead of educational modules for an MSc in Oncology at the Institute of Cancer Research.

She was delighted to transfer full time to the Royal Marsden in autumn 2019 in order to focus on her career in cancer medicine and clinical research; In March 2020 she was appointed to the faculty of the Institute of Cancer Research and also to the role of Associate Medical Director for Strategy at the Royal Marsden. She is also a member of the UK Clinical Strategy Group for Chemotherapy and Systemic Anti-Cancer Therapy.

Dr Pickering has published more than 50 peer-reviewed papers and book chapters and has been involved in more than 70 clinical trials, including as Principle and Chief Investigator. She is a current and past member of National Research Groups for Renal and Bladder and Penile cancers. Her major interest is in improving the outcome of renal, prostate and skin cancers. In particular, she is interested in the development of new treatments, determining how to individualise patient treatment and making those advances available to patients.

Disclosure information not submitted.

Presentation(s):